US Patent

US8053427 — Brimonidine gel composition

Method of Use · Assigned to Galderma Research and Development SNC · Expires 2031-06-13 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a brimonidine gel composition for the treatment of skin disorders.

USPTO Abstract

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Drugs covered by this patent

Alphagan (BRIMONIDINE TARTRATE) · Senju Pharmaceutical Co., Ltd

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1428`	—	Alphagan

Patent Metadata

Patent number: US8053427
Jurisdiction: US
Classification: Method of Use
Expires: 2031-06-13
Drug substance claim: No
Drug product claim: Yes
Assignee: Galderma Research and Development SNC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.